Adaptimmune Therapeutics

NASDAQ: ADAP · Real-Time Price · USD
0.28
-0.00 (-1.06%)
At close: Jun 09, 2025, 3:58 PM

Adaptimmune Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
179.64M 178.03M 175.04M 141.46M 18.36M 60.28M 71.08M 70.77M 71.17M 27.15M 17.54M 11.73M 9.29M 6.15M 6.23M 6.22M 3.63M
Cost of Revenue
3.48M 5.43M 8.3M 11.18M 10.82M 9.85M 30.03M 60.33M 92.84M 127.73M 134.18M 129.21M 123.34M 111.09M 107.36M 103.22M 94.81M
Gross Profit
176.16M 172.6M 166.74M 130.28M 7.54M 50.43M 41.05M 10.43M -21.66M -100.58M -116.64M -117.47M -114.05M -104.94M -101.13M -96.99M -91.18M
Operating Income
-65.23M -68.76M -49.26M -80.87M -194.47M -143.56M -116.78M -113.48M -112.33M -163.97M -179.59M -178.78M -174.34M -162.25M -156.9M -150.59M -141.53M
Interest Income
6.16M 6.6M 6.43M 6.48M 6.65M 5.98M 4.89M 3.07M 1.88M 1.54M 1.2M 1.1M 1.01M 1.09M 1.45M 3.38M 4.26M
Pretax Income
-68.57M -69.54M -49.74M -77.87M -166.32M -116.69M -92.22M -88.33M -111.67M -162.96M -173.35M -174.52M -169.47M -157.3M -155.21M -148.44M -139.3M
Net Income
-69.89M -70.81M -44.93M -72.92M -163.83M -114.29M -95.2M -91.02M -114.16M -165.46M -175.06M -176.04M -170.59M -158.09M -155.84M -148.88M -139.69M
Selling & General & Admin
82.14M 78.59M 71.52M 66.41M 70.12M 70.79M 71.85M 72.5M 69.32M 65.73M 65.29M 63.65M 61.74M 58.76M 57.22M 55.05M 50.35M
Research & Development
142.71M 149.06M 147.18M 150.67M 140.19M 130.53M 116.35M 111.75M 116.52M 127.73M 134.18M 129.21M 123.34M 111.09M 107.36M 103.22M 94.81M
Other Expenses
16.42M 16.36M -374K -698K -197K -807K -2.03M -63K -1.22M -536K 5.04M 3.16M 3.87M 3.85M 230K -1.22M -1.84M
Operating Expenses
243.99M 246.79M 221.43M 219.8M 210.31M 201.31M 188.21M 184.25M 183.5M 191.11M 197.12M 190.51M 183.63M 168.4M 163.13M 156.81M 145.16M
Interest Expense
5.23M 3.35M 1.64M 531K 5K 5K 1.01M 1.34M 1.34M 1.68M 841K 742K 1.01M 1.09M 916K 2.84M 3.72M
Selling & Marketing Expenses
-2.22M -2.22M -5.45M -5.45M -2.73M -2.73M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
242.55M 244.47M 224.3M 222.67M 213.18M 204.19M 188.21M 184.25M 183.5M 191.11M 197.12M 190.51M 183.63M 168.4M 163.13M 156.81M 145.16M
Income Tax Expense
92.92K 141.92K -5.94M -7.46M -4.92M -3.77M 1.61M 2.7M 2.49M 2.5M 1.71M 1.52M 1.13M 792K 634K 441K 390K
Shares Outstanding (Basic)
257.03M 255.94M 255.77M 255.59M 241.87M 227.11M 226.31M 184.69M 165.22M 164.12M 163.47M 160.47M 156.67M 156.22M 156.1M 155.7M 155.18M
Shares Outstanding (Diluted)
257.03M 255.94M 255.77M 259.86M 241.87M 227.11M 226.31M 184.69M 166.71M 164.12M 163.47M 160.47M 156.67M 156.22M 156.1M 155.7M 155.18M
EPS (Basic)
-0.27 -0.29 -0.21 -0.34 -0.72 -0.52 -0.49 -0.54 -0.72 -1.02 -1.08 -1.14 -1.08 -1.02 -1.02 -0.96 -0.9
EPS (Diluted)
-0.27 -0.29 -0.21 -0.34 -0.72 -0.52 -0.49 -0.54 -0.72 -1.02 -1.08 -1.14 -1.08 -1.02 -1.02 -0.96 -0.9
EBITDA
-52.48M -56.25M -38.12M -69.01M -160.99M -116.42M -90.08M -87.84M -109.07M -155.59M -174.95M -174.18M -169.85M -157.91M -155.99M -149.57M -140.09M
EBIT
-65.65M -69.78M -46.52M -77.48M -166.46M -120.92M -96.01M -92.36M -115.41M -161.67M -179.59M -178.78M -174.34M -162.25M -156.9M -150.59M -141.53M
Depreciation & Amortization
10.84M 11.2M 11.27M 11.32M 10.82M 9.85M 8.42M 7.03M 6.33M 6.05M 6.84M 6.81M 6.71M 6.57M 6.05M 6.43M 7.14M